Fig. 2From: Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trialTrial design. SGLT2is: sodium-glucose cotransporter 2 inhibitors; T2D: type 2 diabetesBack to article page